American society of clinical oncology statement: Toward individualized care for patients with advanced cancer

Journal of Clinical Oncology

Volumn 29, Issue 6, 2011, Pages 755-760

  Peppercorn, Jeffrey M ^a   Smith, Thomas J ^a   Helft, Paul R ^a   DeBono, David J ^a   Berry, Scott R ^a   Wollins, Dana S ^a   Hayes, Daniel M ^a   Von Roenn, Jamie H ^a   Schnipper, Lowell E ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

ADVANCED CANCER; CANCER PALLIATIVE THERAPY; CANCER PATIENT; CANCER THERAPY; CLINICAL RESEARCH; CLINICAL TRIAL (TOPIC); EMPOWERMENT; EVIDENCE BASED MEDICINE; HUMAN; INTERPERSONAL COMMUNICATION; MEDICAL DECISION MAKING; MEDICAL EDUCATION; MEDICAL SOCIETY; PATIENT CARE; PATIENT PARTICIPATION; PATIENT PREFERENCE; PRACTICE GUIDELINE; PRIORITY JOURNAL; QUALITY OF LIFE; REVIEW; TERMINAL CARE; TOTAL QUALITY MANAGEMENT;

CLINICAL TRIALS AS TOPIC; HUMANS; INDIVIDUALIZED MEDICINE; MEDICAL ONCOLOGY; NEOPLASMS; SOCIETIES, MEDICAL;

EID: 79952139727     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2010.33.1744     Document Type: Review

References (42)

1. Cancer care during the last phase of life. J Clin Oncol 16:1986-1996, 1998
2. Ferris FD, Bruera E, Cherny N, et al: Palliative cancer care a decade later: Accomplishments, the need, next steps - From the American Society of Clinical Oncology. J Clin Oncol 27:3052-3058, 2009
3. Keating NL, Landrum MB, Rogers SO Jr, et al: Physician factors associated with discussions about end-of-life care. Cancer 116:998-1006, 2010
4. Stubenrauch JM: Study: Few physicians discussing end-of-life options with advanced-stage patients. Oncology Times 32:26, 28, 29, 2010
5. Druker BJ, Guilhot F, O'Brien SG, et al: Fiveyear follow-up of patients receiving imatinib for chronic myeloid leukemia. N Engl J Med 355:2408-2417, 2006 (Pubitemid 44903745)
6. Slamon DJ, Leyland-Jones B, Shak S, et al: Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 344:783-792, 2001 (Pubitemid 32222155)
7. Raab MS, Podar K, Breitkreutz I, et al: Multiple myeloma. Lancet 374:324-339, 2009
8. Kasner MT, Luger SM: Update on the therapy for myelodysplastic syndrome. Am J Hematol 84: 177-186, 2009
9. Coiffier B, Lepage E, Briere J, et al: CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. N Engl J Med 346:235-242, 2002 (Pubitemid 34438862)
10. Hurwitz H, Fehrenbacher L, Novotny W, et al: Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 350:2335-2342, 2004 (Pubitemid 38702844)
11. Rini BI: Metastatic renal cell carcinoma: Many treatment options, one patient. J Clin Oncol 27: 3225-3234, 2009
12. Fojo T, Grady C: How much is life worth: Cetuximab, non-small cell lung cancer, and the $440 billion question. J Natl Cancer Inst 101:1044-1048, 2009
13. Carlson RW, Allred DC, Anderson BO, et al: Breast cancer. Clinical practice guidelines in oncology. J Natl Compr Canc Netw 7:122-192, 2009
14. Engstrom PF, Benson AB 3rd, Chen YJ, et al: Colon cancer clinical practice guidelines in oncology. J Natl Compr Canc Netw 3:468-491, 2005 (Pubitemid 44265422)
15. Ettinger DS, Bepler G, Bueno R, et al: Non-small cell lung cancer clinical practice guidelines in oncology. J Natl Compr Canc Netw 4:548-582, 2006 (Pubitemid 44265463)
16. Okie S: Access before approval: A right to take experimental drugs? N Engl J Med 355:437-440, 2006
17. Peppercorn J, Burstein H, Miller FG, et al: Self-reported practices and attitudes of US oncologists regarding off-protocol therapy. J Clin Oncol 26:5994-6000, 2008
18. Mack JW, Weeks JC, Wright AA, et al: End-of-life discussions, goal attainment, and distress at the end of life: Predictors and outcomes of receipt of care consistent with preferences. J Clin Oncol 28:1203-1208, 2010
19. Temel JS, Greer JA, Muzikansky A, et al: Early palliative care for patients with metastatic nonsmall-cell lung cancer. N Engl J Med 363:733-742, 2010
20. Earle CC, Landrum MB, Souza JM, et al: Aggressiveness of cancer care near the end of life: Is it a quality-of-care issue? J Clin Oncol 26:3860-3866, 2008
21. Robinson TM, Alexander SC, Hays M, et al: Patient-oncologist communication in advanced cancer: Predictors of patient perception of prognosis. Support Care Cancer 16:1049-1057, 2008
22. Zhang B, Wright AA, Huskamp HA, et al: Health care costs in the last week of life: Associations with end-of-life conversations. Arch Intern Med 169:480-488, 2009
23. Wright AA, Keating NL, Balboni TA, et al: Place of death: Correlations with quality of life of patients with cancer and predictors of bereaved caregivers' mental health. J Clin Oncol 28:4457-4464, 2010
24. Harrington SE, Smith TJ: Providing palliative care and transitioning patients to hospice: How oncologists and palliative care specialists can work together. J Community Oncol 7:136-140, 2010
25. Kemeny MM, Peterson BL, Kornblith AB, et al: Barriers to clinical trial participation by older women with breast cancer. J Clin Oncol 21:2268-2275, 2003 (Pubitemid 46621862)
26. Lara PN Jr, Higdon R, Lim N, et al: Prospective evaluation of cancer clinical trial accrual patterns: Identifying potential barriers to enrollment. J Clin Oncol 19:1728-1733, 2001 (Pubitemid 32230874)
27. Somer RA, Sherman E, Langer CJ: Restrictive eligibility limits access to newer therapies in nonsmall-cell lung cancer: The implications of Eastern Cooperative Oncology Group 4599. Clin Lung Cancer 9:102-105, 2008 (Pubitemid 351631921)
28. Vardy J, Dadasovich R, Beale P, et al: Eligibility of patients with advanced non-small cell lung cancer for phase III chemotherapy trials. BMC Cancer 9:130, 2009
29. Surbone A: Communication preferences and needs of cancer patients: The importance of content. Support Care Cancer 14:789-791, 2006
30. Amalraj S, Starkweather C, Nguyen C, et al: Health literacy, communication, and treatment decision-making in older cancer patients. Oncology (Williston Park) 23:369-375, 2009
31. Meropol NJ, Schrag D, Smith TJ, et al: American Society of Clinical Oncology guidance statement: The cost of cancer care. J Clin Oncol 27:3868-3874, 2009
32. Von Roenn JH, von Gunten CF: Setting goals to maintain hope. J Clin Oncol 21:570-574, 2003 (Pubitemid 46606491)
33. Smith TJ, Hillner BE: Explaining marginal benefits to patients, when "marginal" means additional but not necessarily small. Cancer Clin Res 16:5981-5986, 2010
34. Swetz KM, Smith TJ: Palliative chemotherapy: When is it worth it and when is it not? Cancer J 16:467-472, 2010
35. Baile WF, Lenzi R, Parker PA, et al: Oncologists' attitudes toward and practices in giving bad news: An exploratory study. J Clin Oncol 20:2189-2196, 2002 (Pubitemid 34408811)
36. Back AL, Arnold RM, Baile WF, et al: Faculty development to change the paradigm of communication skills teaching in oncology. J Clin Oncol 27:1137-1141, 2009
37. Fallowfield L, Jenkins V, Farewell V, et al: Efficacy of a Cancer Research UK communication skills training model for oncologists: A randomised controlled trial. Lancet 359:650-656, 2002 (Pubitemid 34203764)
38. Snow K, Gever J, Childs D: Experts Debunk Health Care Reform Bill's 'Death Panel' Rule. ABC News, August 11, 2009
39. Spettell CM, Rawlins WS, Krakauer R, et al: A comprehensive case management program to improve palliative care. J Palliat Med 12:827-832, 2009
40. Joly F, Vardy J, Pintilie M, et al: Quality of life and/or symptom control in randomized clinical trials for patients with advanced cancer. Ann Oncol 18: 1935-1942, 2007
41. Booth CM, Tannock I: Reflections on medical oncology: 25 years of clinical trials - where have we come and where are we going? J Clin Oncol 26:6-8, 2008
42. Pollak KI, Arnold RM, Jeffreys AS, et al: Oncologist communication about emotion during visits with patients with advanced cancer. J Clin Oncol 25:5748-5752, 2007